Healthcare-focused private equity firm Oberland Capital raised $800 million for its second royalty and credit opportunities fund, surpassing its $650 million target.

Oberland Capital Healthcare II LP received capital commitments from pension plans, financial institutions, foundations and endowments in the U.S., Europe and the Middle East.

The fund aims to invest between $20 million and $150 million in commercial-stage or near-commercial-stage biopharmaceutical, medical device and diagnostic companies, as well as royalty-bearing products.